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CHARGE association is characterized by ocular Coloboma, Heart malformations, choanal Atresia, Retardation of
growth and development, Genital abnormalities and inner and external Ear abnormalities. Growth failure is a
frequent find mainly associated with feeding difficulties or systemic diseases. To date, GH deficiency has been
reported in only few patients with CHARGE association however long-term effects of GH treatment, up to final
height, have never been reported. We describe a patient with CHARGE association and GH deficiency treated with
GH from the age of 3 years and 10 months up to adult height.
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CHARGE association is a multiple-malformation syndrome
that includes ocular Coloboma, Heart malformations,
choanal Atresia, Retardation of growth and develop-
ment, Genital abnormalities and inner and external Ear
abnormalities [1]. The majority of subjects with CHARGE
association presents mutations involving the chromodo-
main helicase DNA-binding protein-7 (CHD7) gene on
chromosome 8q12 [2].
Developmental delay and growth retardation become
more evident with age. At birth, children with CHARGE
association usually have normal weights and lengths and
the most marked decline away from the centiles is ob-
served during infancy with a significant limited catch-up
growth in stature [3]. Although anterior pituitary dysfunc-
tion has not always been identified as the cause of growth
failure in patients with CHARGE association, GH defi-
ciency (GHD) has been reported in few cases [3-5]. To
our knowledge, only two patients with CHARGE associ-
ation and GH deficiency have been treated with recombin-
ant GH therapy [6] but the impact of long-term therapy
has not been reported so far.* Correspondence: salerno@unina.it
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unless otherwise stated.Hereby we report a case of a patient with CHARGE
association and GHD treated with GH from the age of
3 years and 10 months up to final height.Case presentation
The patient was a boy born by cesarean delivery at
40 weeks of gestation following a pregnancy complicated
by polidramnios. He was the first of three children born
to healthy, non-consanguineous parents. His birth
weight was 2.800 kg (−1.6 SDS) with an Apgar score of
5 at 1 minute and 6 at 5 minutes. At birth he was admit-
ted to Neonatal Intensive Care Unit with respiratory dis-
tress and underwent surgical treatment for esophageal
atresia. At physical examination he showed dismorphic
facial features (external ear sloping forehead, flattened
tip of nose, left microphtalmia), nistagmus and general
hypotonia. The ophtamological inspection showed colo-
boma of retina involving the optic nerve. Visual evoked
response showed immature waves. Diagnostic exams
aimed at recognizing malformations were performed: ab-
domen ultrasound was normal and renal anomalies were
not detected; echocardiogram revealed aortic arch ecta-
sia and aortic valve regurgitation.
At 12 months of life speech delay was noted and audi-
tory brainstem response showed mixed deafness. Hearing
aid device and logopedic rehabilitation were required.
At the age of 14 months the patient developed gastroeso-
phal reflux, that required medical treatment. Psychomotorl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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life. Throughout childhood his language and social
skills progressed but remained moderately delayed.
Challenging behaviors including agitation, depression,
anxiety and problem with selfregulation required be-
havior therapy.
Based on these clinical features, CHARGE association
was suspected and genetic investigations were per-
formed. Karyotype was normal and excluded 22q11 dele-
tion as well as abnormalities of chromosomes 22, 14,
and 9; fluorescent in situ hybridization excluded 22q11
deletion; CHD7 gene mutation testing showed heterozy-
gotic mutation c. 4789_4790 of the exon 21.
Because of severe growth impairment by the age of
3 years and 10 months he underwent endocrine evalu-
ation. Height was 88.3 cm (−2.95 SDS), quite below the
target height (TH) (170.5 cm, −0.96 SDS), BMI SDS was
−0.86, growth velocity was 4.8 cm/year (−2.09 SDS) [7]
and bone age was more than 2 years delayed with re-
spect to chronological age.
Malnutrition and systemic causes of short stature were
excluded, thyroid function was normal while IGF-1 con-
centration was low (28 ng/ml, −1.17 SD).
GH secretion, evaluated after two different pharmaco-
logical tests, showed a mild GH deficiency (GH peak after
L-DOPA 6.0 ng/ml and GH peak after arginine 6.8 ng/ml
respectively) [8]. Hypothalamus-pituitary region magnetic
resonance imaging showed partial empty sella.
Therapy with recombinant GH was initiated at the age
of 3 years and 10 months at the dosage of 30 μg/kg/die
with a consequent increase in growth velocity to 7.7 cm/
year (0.77 SDS). No additional hormone deficiencies were
observed during follow-up. A mild increase in serum
TSH levels (TSH 5.0 mU/l) with normal FT4 was ob-
served during the last two years of GH treatment; how-
ever that did not required any therapy [9]. Wechsler
Intelligence Scale for Children performed at the age of
10 years confirmed mild developmental delay (Intelligence
Quotient 67). Pubertal development began spontaneously
at the age of 13 years and 4 months and progressed regu-
larly. No GH-related adverse events occurred during the
follow-up.
At the age of 17 years and 10 months GH treatment
was stopped. His adult height was 164 cm (−1.80 SDS),
in the low range of his TH (Figure 1).
Discussion
CHARGE association is a well-established multiple-
malformation syndrome that includes Coloboma, Heart
defect, Atresia choanae, Retarded growth and develop-
ment, Genital hypoplasia, Ear anomalies/deafness [1].
A diagnosis of CHARGE association should be con-
sidered in any infant with coloboma, choanal atresia,
asymmetric facial palsy or classical CHARGE ears incombination with other specific congenital anomalies
[1]. Individuals with all four major characteristics (the
classical 4C’s: Choanal atresia, Coloboma, Characteris-
tic ears and Cranial nerve anomalies) or three major
and three minor characteristics are highly likely to have
CHARGE association [1,10].
CHD7 has been reported to be a causative gene of
CHARGE association and mutations in this gene have
been reported in the majority of patients with CHARGE
association [11]. In situ hybridization analysis of the
CHD7 gene during early human development showed a
good correlation between CHD7 expression patterns and
the developmental anomalies observed in CHARGE as-
sociation [12].
CHD7 expression has been reported within the hypo-
thalamus and pituitary gland suggesting that endocrine
deficiencies may occur in CHARGE association as conse-
quence of the differentiation of either the hypothalamic
nuclei or the trophic cells of the anterior pituitary [5,12].
Indeed, CHD7 has been described to be a SOX2 cofactor
which is an important regulator of hypothalamic-pituitary
axis [13]. In fact, structural pituitary abnormalities as an-
terior pituitary hypoplasia and ectopic posterior pituitary
have been reported in patients with CHARGE association
[6,14].
Hypogonadotropic hypogonadism (HH) is the most
frequent endocrine feature described in CHARGE asso-
ciation [5] whilst GH, TSH and ACTH deficiencies have
been occasionally reported [6].
In some cases HH may be responsible for the hypogenit-
alism which is considered a major feature of CHARGE as-
sociation presenting in males with micropenis and/or
cryptorchidism in infancy while females usually do not
show evidence of genital hypoplasia [15]. Conversely, de-
layed puberty and biochemical findings of HH (FSH
and LH low or undetectable) have been reported in
both male and female subjects [4-6,14,15]. In our pa-
tient, however, HH was excluded by the presence of
normal genitalia in infancy (penis length 4.7 cm with
normal testes in the scrotum at the age of 3 years and
10 months) and by spontaneous pubertal development
during adolescence.
Moreover, growth retardation is an hallmark of CHARGE
association. Most children have normal length at birth
[3] however, suboptimal postnatal linear growth may
occur in up to 90% of subjects, especially in the first
three years of life [4]. Therefore, mean adult height is
usually at or below the 3rd percentile [4,10] even if the
attainment of normal adult height has been occasion-
ally reported [16]. In CHARGE association growth fail-
ure is frequently due to feeding difficulties or renal,
gastrointestinal, cardiovascular anomalies. However,
few patients with CHARGE association have been diag-
nosed to have GH deficiency [5,6,13]. GH-IGF1 axis
Figure 1 Linear growth of the patient before and during GH therapy up to adult height.
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However, GH treatment is not always associated with
optimal results in term of linear growth [17]. Only two
other patients with CHARGE association have been so
far treated with GH [6]. They presented multiple pituit-
ary hormone deficiencies with small anterior pituitary
and ectopic posterior pituitary. Short-term GH therapy
was associated with a significant increase in growth vel-
ocity; however, in these patients long-tem effects of
GH-treatment are not yet appreciable as they have not
yet reached puberty and final height.
To our knowledge, it is the first report of long-term
(14 years) GH treatment in a patient with CHARGE as-
sociation. In our patient GH deficiency was documented
after the exclusion of other systemic causes of shortstature. Moreover, the radiological finding of partial
empty sella was consistent with GHD diagnosis. GH
treatment was associated with a great improvement in
growth rate and resulted in a final height appropriate to
his genetic target without any adverse event.
Conclusions
Our report confirms that growth retardation in CHARGE
association can be due to GH deficiency and that in these
patients long-term GH treatment can have a significant
positive effect on growth velocity and adult height. There-
fore, biochemical evaluation of GH-IGF1 axis should be
performed in children with CHARGE association and
growth retardation after exclusion of malnutrition and
other causes of systemic diseases.
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